CTOs on the Move

Jubilant Clinsys

www.clinsys.com

 
Clinsys practices this philosophy with its clients. We focus on building long-term relationships and successful partnerships with our pharmaceutical and biotech partners through a total dedication to delivering on commitments, understanding client needs
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.clinsys.com
  • 1 Crossroads Dr Bldg A
    Bedminster, NJ USA 07921
  • Phone: 908.947.7777

Executives

Name Title Contact Details

Similar Companies

Synecor

Synecor is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lexaria Bioscience

Lexaria Bioscience Corp. has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds. Lexaria has multiple patents pending and granted in over 40 countries around the world and was granted its first patent in the USA in October, 2016. Lexaria`s technology provides increases of up to 10x in intestinal absorption rates; more rapid delivery to the bloodstream with effects often within 15-20 minutes; and important taste-masking benefits, for orally administered bioactive molecules including but not limited to cannabinoids, vitamins, NSAIDs, and nicotine.

BIOWEST THERAPEUTICS

BIOWEST THERAPEUTICS Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Temporary Technical Services Inc

Temporary Technical Services Inc is a Jackson, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affigen

Affigen was founded in 2016 by Frameshift, a firm that ideates, translates and launches life sciences companies that have the potential to fundamentally shift the metabolic rate of the industry. In February 2017, Affigen completed its Series A funding, led by Black Beret Life Sciences on behalf of its affiliate BBLS Immunotherapy, LLC. Black Beret Life Sciences is the life sciences investment management arm of the Houston-based Bosarge Family Office. The firm was established in 2014 by Dr. Ed Bosarge to organize and manage investments in potentially game-changing technologies and companies in areas related to regenerative medicine, anti-aging and immunotherapy. Black Beret Life Sciences’ portfolio of managed investments includes companies and research across an array of disease areas, including diabetes, neurodegeneration, osteoarthritis, cancer immunotherapy and various conditions related to aging.